In Brief: Dade
This article was originally published in The Gray Sheet
Executive SummaryDade: Completes acquisition of DuPont Medical Products' In Vitro Diagnostics business, the firm announces May 8. The merger, announced in December 1995, creates the largest stand-alone diagnostics firm, with $1 bil. in annual sales ("The Gray Sheet" Dec. 18, 1995, p. 12)...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.